Thus, ORAOV1 expression may serve as a predictive biomarker for response to immune checkpoint blockade, and its targeted inhibition may represent a promising strategy to enhance immunotherapy efficacy in HCC. Here, LTO1 is linked to hepatocellular carcinoma.